1. Home
  2. VGZ vs RZLT Comparison

VGZ vs RZLT Comparison

Compare VGZ & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$2.18

Market Cap

295.7M

Sector

N/A

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.82

Market Cap

321.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
RZLT
Founded
1983
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.7M
321.6M
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
VGZ
RZLT
Price
$2.18
$3.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$3.75
$9.67
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.32
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$1.07
52 Week High
$3.13
$11.46

Technical Indicators

Market Signals
Indicator
VGZ
RZLT
Relative Strength Index (RSI) 46.60 55.35
Support Level $2.02 $2.91
Resistance Level $2.43 $4.09
Average True Range (ATR) 0.14 0.33
MACD -0.02 0.07
Stochastic Oscillator 28.92 46.63

Price Performance

Historical Comparison
VGZ
RZLT

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: